ArticleNPJ precision oncology2026

Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma.

Zengfei Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.